REPL Stock Overview
A clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Replimune Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.37 |
| 52 Week High | US$24.33 |
| 52 Week Low | US$4.92 |
| Beta | 1.16 |
| 1 Month Change | 22.83% |
| 3 Month Change | -1.93% |
| 1 Year Change | -64.93% |
| 3 Year Change | -76.37% |
| 5 Year Change | -38.04% |
| Change since IPO | -44.82% |
Recent News & Updates
Recent updates
Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06
Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Shareholder Returns
| REPL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.9% | 0.02% | 1.2% |
| 1Y | -64.9% | 6.7% | 20.6% |
Return vs Industry: REPL underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: REPL underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| REPL volatility | |
|---|---|
| REPL Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: REPL's share price has been volatile over the past 3 months.
Volatility Over Time: REPL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 331 | Sush Patel | www.replimune.com |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.
Replimune Group, Inc. Fundamentals Summary
| REPL fundamental statistics | |
|---|---|
| Market cap | US$580.99m |
| Earnings (TTM) | -US$215.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.4x
P/E RatioIs REPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REPL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$215.79m |
| Earnings | -US$215.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 12.0% |
How did REPL perform over the long term?
See historical performance and comparison